Can one box of ensifentrine-Ohtuvayre last for one year?

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is a new type of inhaled drug, mainly used to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). Its unique mechanism of action helps improve patients' respiratory conditions and lung function through dual effects on bronchodilation and anti-inflammatory responses.

The specifications of each box of Exefantine are3mg/2.5mL (60 doses). Each unit dose ampoule is suitable for use twice a day, that is, inhaled once in the morning and evening every day. Therefore, the usage period of one box of medicine is 30 days. If used at the recommended dosage and frequency, each box of medication will last up to one month.

If a patient plans to use exefantine for long-term treatment, one box of the drug will not last for a year. Depending on the patient's treatment needs and the severity of the disease, more medications may need to be prepared for long-term use. Taking one year as an example, patients will need approximately 12 boxes of medication to maintain their monthly treatment plan. Therefore, it is important to ensure a continuous supply of medications for COPD patients who require long-term treatment.

Since ensefentin has not yet been officially launched in China and is not included in medical insurance, the price of the drug is relatively high, so patients may face a greater financial burden. In this case, patients need to plan the purchase and use cycle of the drug in advance. Patients can consider purchasing drugs through formal channels and communicate with their doctors about whether there are other drug alternatives to reduce the cost of long-term treatment.

In addition, patients should undergo regular reexamination during long-term use to ensure the effectiveness of the drug and avoid the occurrence of adverse reactions. Although the safety and efficacy of exefantine have been clinically proven, it is still important to monitor respiratory function and cardiovascular health during long-term use.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html